|
Dec 29
|
Fate Therapeutics Insiders US$207k Short Of Breakeven On Stock Purchase
|
|
Dec 22
|
Fate Therapeutics (FATE) Upgraded to Buy: Here's Why
|
|
Dec 18
|
12 Most Promising Cancer Stocks According to Analysts
|
|
Dec 8
|
Fate Therapeutics (FATE) Up 10.3% Since Last Earnings Report: Can It Continue?
|
|
Aug 9
|
FATE Q2 Earnings Beat on Lower Expenses, Revenues Miss
|
|
Aug 9
|
Q2 2023 Fate Therapeutics Inc Earnings Call
|
|
Aug 8
|
Fate Therapeutics (FATE) Reports Q2 Loss, Lags Revenue Estimates
|
|
Aug 8
|
Fate Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates
|
|
Jun 16
|
Why Shares of Fate Therapeutics Soared This Week
|
|
Apr 27
|
Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Should You Buy?
|
|
Apr 26
|
Fate Therapeutics (FATE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
|
|
Apr 24
|
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2023 Financial Results
|